Cleveland Clinic Cancer Advances
Biosignature Predicts Benefit of Adjuvant Radiotherapy in Patients With DCIS
16 Dec 2021
Description
Results from a multi-institutional study led by a Cleveland Clinic researcher, DCSionRT®, a biosignature based on multiple biomarkers, may hold the key to solving the treatment of ductal carcinoma in situ (DCIS). Chirag Shah, MD, coinvestigator, and director of Breast Radiation Oncology at Cleveland Clinic joins the Cancer Advances podcast to explain the study and findings that were presented at the American Society for Radiation Oncology annual meeting (ASTRO).
Audio
Featured in this Episode
No persons identified in this episode.
Transcription
No transcription available yet
Help us prioritize this episode for transcription by upvoting it.
0
upvotes
Popular episodes get transcribed faster